📦New Duties on Low-Value Imports from China to Combat Opioid Crisis
Executive Order 14256 addresses the illicit shipment of synthetic opioids from the People’s Republic of China and Hong Kong. The order revokes duty-free treatment for low-value imports, mandating new duty payments on eligible products entered for consumption after May 2, 2025. It aims to enhance U.S. trade compliance and revenue collection while monitoring the opioid crisis' impact.
Learn More📉Executive Order Raises Tariffs on Chinese Imports for Opioid Crisis
Executive Order 14228 addresses the ongoing threat posed by synthetic opioids, specifically from China. The order amends previous executive actions and increases tariffs on related products, citing insufficient action by the PRC to mitigate this issue. The measure emphasizes national security concerns linked to drug trafficking and economic stability.
Learn More⚖️Executive Order Imposes Tariffs on Chinese Goods to Combat Opioid Crisis
Executive Order 14195 addresses the urgent synthetic opioid crisis exacerbated by the People's Republic of China's role in drug trafficking. It imposes a 10% duty on PRC products effective February 4, 2025, as a response to the failure of Chinese authorities to curb the flow of dangerous substances. The order emphasizes a commitment to protecting American citizens and addressing the growing public health emergency.
Learn More